secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001213900-26-039992
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne shareholders approve reverse stock split and 1.5M share increase in equity plan
--------------------------------------------------------------------------------

- Shareholders approved reverse stock split at ratio of 1-for-2 to 1-for-15; board to determine final ratio.
- Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 1,500,000 and adding 5% annual evergreen increase starting 2027.
- Elected Jeffrey Mathiesen and Edward Andrle as Class III directors for three-year terms.
- Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending September 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026039992/0001213900-26-039992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026039992/ea0285085-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-039992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer